Search the Newsreel

EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis

EyePoint Pharmaceuticals Inc (EYPT) currently holds a financial score of 6.13, ranking 143 out of 155 in the pharmaceuticals industry, indicating stable financial status but low operating efficiency. The company reported a significant year-over-year revenue decrease of 97.15% to $696.00K and an 87.70% decrease …

BlackRock, Inc. (NASDAQ: EYPT) discloses 7.7% beneficial stake in EyePoint

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.7% in EyePoint Pharmaceuticals, Inc., totaling 6,430,477 shares of common stock. BlackRock holds sole voting power over 6,290,331 shares and sole dispositive power over all 6,430,477 shares. The filing clarifies that …

Did EyePoint's (EYPT) Federal Settlement and 5‑Year Integrity Deal Just Reframe Its Risk Profile?

EyePoint, Inc. recently settled with U.S. federal authorities over past sales and marketing practices, agreeing to pay approximately US$4.68 million and entering a five-year Corporate Integrity Agreement. This settlement, while adding compliance overhead, is considered modest relative to the company's historical losses and does …

EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of EyePoint Pharmaceuticals Inc (EYPT), outlining major institutional holders and their proportional stakes. It provides data on top shareholders like Cormorant Asset Management and Suvretta Capital Management, and categorizes shareholder types such as hedge funds and investment advisors. …

EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of EyePoint Pharmaceuticals Inc (EYPT) regarding its dividends and stock splits. It indicates that EYPT has not distributed any dividends over the past five years. However, it lists multiple stock split events that occurred on December 8, 2020, …

EyePoint Pharmaceuticals Inc (EYPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a revenue breakdown for EyePoint Pharmaceuticals Inc (EYPT), detailing its business segments and regional revenue contributions. The data is presented for various fiscal years, with YUTIQ being the primary business segment and the United States as the dominant regional revenue source. …

EyePoint Pharmaceuticals Inc

Commodore Capital LP Acquires Shares of 2,825,000 Eyepoint Pharmaceuticals, Inc. $EYPT

EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280

EyePoint Pharmaceuticals Inc (EYPT) is a clinical-stage biopharmaceutical company focused on developing therapies for serious retinal diseases. Despite a recent stock market dip, its fundamentals are healthy, and growth potential is significant, with institutional ownership being very high. Analysts currently rate the stock as …

EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence

EyePoint Pharmaceuticals Inc (EYPT) currently holds an institutional shareholding score of 10.00, placing it first among 155 companies in the Pharmaceuticals industry. While the institutional shareholding proportion is 105.59%, this represents a 16.25% decrease quarter-over-quarter. Key institutional shareholders include Cormorant Asset Management, Suvretta Capital …

Walleye Capital LLC Makes New Investment in Eyepoint Pharmaceuticals, Inc. $EYPT

Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations

EyePoint, Inc., a Watertown-based company, has agreed to pay nearly $4.7 million to settle allegations under the False Claims Act and Anti-Kickback Statute. The government accused EyePoint of paying illegal kickbacks to Ambulatory Surgery Centers (ASCs) to encourage the purchase of its drug, DEXYCU, …

Drug company to pay $4.7M after admitting it paid providers to use its product

EyePoint Pharmaceuticals has agreed to pay $4.7 million to resolve claims of a kickback scheme involving its drug DEXYCU. The company admitted to using "Assurance Program" and providing free samples to induce ambulatory surgery centers to purchase and dispense the drug, violating Anti-Kickback Statute …

Is EyePoint (EYPT) Recasting Its R&D Strategy With Dr. Hassan’s Appointment at the Helm?

EyePoint Pharmaceuticals has appointed Dr. Tarek S. Hassan, a renowned retina specialist, as Senior Vice President and Chief Strategic Science Officer. This appointment aims to strengthen the scientific leadership around EyePoint's lead program, DURAVYU, and its pipeline, ahead of pivotal trial data and potential …

EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations

EyePoint Pharmaceuticals has agreed to pay over $4.6 million to settle False Claims Act allegations related to kickbacks and excessive free samples used to promote its eye drug DEXYCU. The company allegedly induced surgery centers to purchase and dispense the drug between 2019 and …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 4.9% - Still a Buy?

Two New EyePoint Employees Receive Options for 63,500 Shares

EyePoint (Nasdaq: EYPT) granted non-statutory stock options for up to 63,500 common shares to two new employees on July 15, 2026, as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $13.85, a ten-year term, and vest over four …

Stifel initiates EyePoint stock with buy rating on retinal drug potential

Stifel has initiated coverage on EyePoint Inc. with a buy rating and a $40.00 price target, citing the potential of its sustained-delivery retinal disease treatment, Duravyu. The drug is expected to offer extended treatment intervals for patients with retinal diseases and its pivotal study …